Drug Profile

Estrogen/progestin extended release - Lyndra

Alternative Names: LYN-035

Latest Information Update: 31 Oct 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lyndra
Class Hormonal contraceptives; Hormonal replacements
Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued HIV infections; Pregnancy

Most Recent Events

17 Oct 2022 Discontinued for HIV infections (Prevention) in USA (PO) prior to October 2022 (Lyndra pipeline, October 2022)
17 Oct 2022 Discontinued for Pregnancy (Prevention) in USA (PO) prior to October 2022 (Lyndra pipeline, October 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com